GMPi group

GMPi is an early-stage biotechnology company dedicated to developing novel small molecule therapeutics for autoimmune and inflammatory diseases. The company's primary focus is the inhibition of glucose-6-phosphate isomerase (GPI), a glycolytic enzyme that has been identified as a critical autoantigen and driver of inflammation in rheumatoid arthritis. Founded by leading immunologists from Harvard Medical School, GMPi aims to translate fundamental insights into the role of GPI in immune-mediated pathology into a new class of disease-modifying treatments. The company's lead programs are currently in the pre-clinical stage, targeting the disruption of the inflammatory cascade to provide more effective options for patients with chronic joint destruction.